Product lifecycle management (LCM) is an integral part of portfolio continuation and preservation. With R&D productivity stalling, and profit margins increasingly eroded by cost-containment initiatives, maximizing the return on investment (ROI) of in-line brands is a key objective for pharmaceutical companies.
Scope
Overview of product reformulation new formulations and combination products; and how, when, and why manufacturers implement reformulation strategies
Review of reformulations in cardiovascular, CNS, diabetes, and women's health
Comparison of successful and less effective reformulation strategies recently implemented, and evaluation of future reformulation strategies
In depth case study analysis, utilizing IMS data to examine launch timing, marketing and promotion, pricing strategies and satisfaction of unmet needs
Report Highlights With reformulation forming an established, and ever growing part of product LCM, it is important that manufacturers fully evaluate the suitability and likely profitability of such a strategy before implementation, as failure to do so will significantly impact the uptake of the reformulation and ultimately reduce the drug's return on investment.
Reformulation is a widely employed LCM technique, of the 50 top manufacturers in 2005, 39% of total product launches from 20022005 were reformulations.
Recently, CNS and alimentary and metabolic therapies have been the most frequently targeted for reformulation; indicative of the large number of treated patient populations, high commercial value, and the highly competitive nature of the markets.
Reasons to Purchase
Understand how companies employ reformulations throughout different stages of the parent product's lifecycle
Assess the relative success and failures of reformulation strategies across both the US and EU markets
Gain insight into how competitive differentiation, pricing, promotion and launch timing influence the success of reformulation strategies
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
